Douglas.avenburg,.D Clinical Professor, Department of Emergency Medicine, Christiana Care Health Systems Douglas Lavenburg, MD is a member of the following medical societies: American Society of Cataract and Refractive Surgery Disclosure: Nothing to disclose. Beneficial effects of green tea — a review. There are programs and support that can help. Turmeric may increase the risk of bleeding. Archives of Ophthalmology. Uveitis can be caused by autoimmune disorders, including rheumatoid arthritis or ankylosing spondylitis . In some cases, biologic response modifiers BRM, or biologic, such as, adalimumab, infliximab, daclizumab, abatacept, and rituximab are used. Has been linked to individuals suffering from rheumatologic, skin, gastrointestinal, lung and infectious diseases. It is often called iritis because it usually only affects the iris, the coloured part of the eye. To learn more about other important symptoms and complications, refer to symptoms of uveitis . Oral corticosteroids tablets or capsules are the strongest form of corticosteroids. AMA Ophthalmology. They can include: If you have any of these symptoms, you should see a doctor right away. Call 911 for all medical emergencies.
( IDRA ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today announced the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform. In the presentation, entitled Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides, Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense. This presentation also provided a demonstration of 3GAs specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. Based on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. no dataAbout Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html
It primarily affects people ages 20 to 50, but it may also affect children. http://www.alabamascholars.org/newgabrielprice/2016/09/13/astute-programs-in-glaucoma-simplified/Fermi: Fermi Clinical Advisor 2015, 1st ed. This can be as simple as reading an eye chart. If the uveitis is caused by a body-wide infection, treatment may involve antibiotics and powerful anti-inflammatory medicines called corticosteroids. Exposure to toxic chemicals such as pesticides and acids used in manufacturing processes also can cause uveitis. homoeopathic remedies have not been studied scientifically for uveitis. Eating more antioxidant-rich foods is good for eye health and your overall health. Uveitis is often grouped by the part of the urea it affects. You’ll need to see an eye specialist called an ophthalmologist. papillary examination may reveal direct photo phobia when the light is directed into the affected eye, as well as consensual photo phobia when light is directed into the uninvolved eye; consensual photo phobia is typical of iritis, whereas photo phobia due to more superficial causes, such as conjunctivitis, is direct but not consensual.